Alamar Biosciences
ALMR
27.77
-4.49
-13.92%
Alamar Biosciences
US · ALMR
#2657 by market cap
Listed 2026
27.77
-4.49
-13.92%
Live - 5344 symbols - heartbeat 50s ago
· 2026-10-08 07:00
Pre-market
28.06
+1.04%
After-hours
28.50
+2.63%
Overnight
27.90
+0.47%
- Market cap
- 1.93B
- P/E (TTM)i
- -38.78
- P/Bi
- 6.16
- EPSi
- -0.54
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on ALMR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.58, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Latest year +195.17% YoY
Margins
- Gross margin
- 56.20%
- Operating margin
- -42.22%
- Net margin
- -40.18%
Key ratios & quality
- Enterprise valuei
- 1.91B
- Altman Z-Scorei
- 2.58
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 25.14M | 74.21M |
| Gross profit | 8.61M | 41.71M |
| Selling & admin expenses | 18.94M | 35.57M |
| Research & development | 39.23M | 37.47M |
| Operating profit | -49.57M | -31.33M |
| Pretax profit | -47.06M | -29.15M |
| Tax | 13.00K | 665.00K |
| Net profit | -47.07M | -29.82M |
| Basic EPS | -1 | 0 |
| Diluted EPS | -0.71 | -0.45 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | 13.09M | 16.16M | 26.04M | 29.43M |
| Gross profit | 6.39M | 8.58M | 14.46M | 17.72M |
| Selling & admin expenses | 6.64M | 7.61M | 13.79M | 17.43M |
| Research & development | 8.30M | 8.90M | 13.02M | 13.82M |
| Operating profit | -8.55M | -7.92M | -12.35M | -13.53M |
| Pretax profit | -7.66M | -7.02M | -20.86M | -13.29M |
| Tax | 0 | 0 | 464.00K | -93.00K |
| Net profit | -7.66M | -7.02M | -21.33M | -13.20M |
| Basic EPS | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.12 | -0.11 | -0.32 | -0.22 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 106.70M | 94.71M |
| Cash & ST investments | 79.36M | 30.00M |
| Inventory | 14.41M | 38.48M |
| Total assets | 149.51M | 139.99M |
| Total current liabilities | 16.59M | 23.73M |
| Short-term debt | 1.91M | 2.10M |
| Long-term debt | -- | 9.81M |
| Total liabilities | 282,922,000.00 | 298,946,000.00 |
| Total equity | -133.41M | -158.95M |
| Retained earnings | -138.96M | -168.78M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 141.47M | 331.38M |
| Cash & ST investments | -- | -- | 64.59M | 250.05M |
| Inventory | -- | -- | 39.93M | 45.41M |
| Total assets | -- | -- | 186.45M | 390.98M |
| Total current liabilities | -- | -- | 24.05M | 27.96M |
| Short-term debt | -- | -- | 1.60M | 2.28M |
| Long-term debt | -- | -- | 74.97M | 9.95M |
| Total liabilities | -- | -- | 364,522,000.00 | 78,118,000.00 |
| Total equity | -- | -- | -178.07M | 312.86M |
| Retained earnings | -- | -- | -190.10M | -203.30M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -55.21M | -53.61M |
| Depreciation & amortization | 3.19M | 3.86M |
| Free cash flow | -58.60M | -59.99M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | 940.00K | 1.49M |
| Ending cash balance | 31.68M | 34.91M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -13.07M | -11.88M | -20.35M | -11.32M |
| Depreciation & amortization | 888.00K | 919.00K | 1.17M | 1.13M |
| Free cash flow | -14.05M | -13.00M | -21.13M | -15.07M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | 243.00K | 164.00K | 1.80M | 205.77M |
| Ending cash balance | 36.00M | 42.57M | 69.49M | 139.22M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -31.48 | -20.60 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -178.91 | -38.74 |
| FCF / sales %i | -- | -- |
| Current ratioi | 6.43 | 3.99 |
| Quick ratioi | 5.22 | 1.80 |
| Debt / assetsi | 22.14 | 29.63 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -21.65 | -71.70 |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -15.87 |
| ROA %i | -- | -- | -23.32 | -12.70 |
| ROIC %i | -- | -- | -- | -14.03 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -47.94 | -47.67 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 5.88 | 11.85 |
| Quick ratioi | -- | -- | 3.50 | 9.67 |
| Debt / assetsi | -- | -- | 56.61 | 13.15 |
| LT debt / equityi | -- | -- | -- | 15.70 |
| Interest coveragei | -- | -- | -72.28 | -63.49 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.